Online citations, reference lists, and bibliographies.

Please confirm you are human

(Sign Up for free to never see this)

← Back to Search

DOI: 10.1002/pbc.26375

Liposomal Doxorubicin: Effective Treatment For Pediatric Desmoid Fibromatosis

P. Ananth, Annette M Werger, S. Voss, C. Rodríguez-Galindo, K. Janeway

Published 2017 · Medicine

Save to my Library

Download PDF

Analyze on Scholarcy

Share

Efficacy of liposomal doxorubicin (LD) in treating desmoid fibromatosis (DF) in children has not been well evaluated. This retrospective case series examines five children with progressive DF, treated with LD. We report progression‐free intervals (PFIs) and radiographic as well as clinical responses for each medication received. LD was well tolerated, with an average 4.5% reduction in tumor size and median PFI of 29 months. Treatment with LD conferred the longest PFI of all medical therapies pursued. Thus, LD is an important treatment option for DF in pediatrics.

This paper references

10.1016/J.YDER.2011.01.021

Aggressive Fibromatosis in Children and Adolescents: The Italian Experience

A. Zaenglein (2011)

10.1002/cncr.24679

Aggressive fibromatosis in children and adolescents

C. Meazza (2010)

10.1016/S0360-3016(00)00566-6

Long-term results with radiation therapy for pediatric desmoid tumors.

T. Merchant (2000)

10.1093/ANNONC/MDS298

The treatment of desmoid tumors: a stepwise clinical approach.

S. Bonvalot (2012)

Safety and efficacy of highdose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) phase II study

SX Skapek (2013)

10.1159/000081337

Response of Progressive Fibromatosis to Therapy with Liposomal Doxorubicin

10.1097/MPH.0b013e3182678d25

Hydroxyurea Treatment Can Avoid the Need for Aggressive Surgery in Pediatric Fibromatosis

G. Bisogno (2013)

10.1200/JCO.2010.33.5489

Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation.

S. Salas (2011)

SUPPORTING INFORMATION Additional Supporting Information may be found online in the supporting information tab for this article

10.1158/1078-0432.CCR-10-1177

Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial

R. Chugh (2010)

Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. Pediatric Blood & Cancer

P Ananth (2017)

10.1016/j.ejca.2008.06.038

Multimodality treatment of mesenteric desmoid tumours.

M. Bertagnolli (2008)

10.1200/JCO.2006.08.2966

Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial.

S. Skapek (2007)

10.1093/annonc/mdr051

Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG).

D. Garbay (2012)

10.1093/annonc/mdq341

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.

N. Penel (2011)

10.1016/j.ejca.2009.08.016

Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.

A. Constantinidou (2009)

10.1016/j.ejca.2008.10.026

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

E. Eisenhauer (2009)

10.1148/rg.335125214

Response criteria in oncologic imaging: review of traditional and new criteria.

T. Tirkes (2013)

10.1002/pbc.24457

Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study

S. Skapek (2013)

10.1016/j.jpedsurg.2012.10.017

Desmoid fibromatosis in children and adolescents: a conservative approach to management.

Joshua N. Honeyman (2013)

10.1158/1078-0432.CCR-10-3322

Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis

M. Gounder (2011)

10.1002/JSO.10104

Desmoid tumors: A novel approach for local control

C. Baliski (2002)

10.1002/14651858.CD005006.pub3

Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

E. C. van Dalen (2006)

This paper is referenced by

10.17116/ONKOLOG2019803115180

Experience with doxorubicin and dacarbazine in the treatment of unresectable extraabdominal desmoid fibromas

A. V. Yadrina (2019)

10.1097/MOP.0000000000000767

An update in the management of pediatric sarcoma.

Gideon Sandler (2019)

10.21147/j.issn.1000-9604.2017.05.10

Efficacy of vinorelbine combined with low-dose methotrexate for treatment of inoperable desmoid tumor and prognostic factor analysis.

10.1002/pbc.26968

Pazopanib therapy for desmoid tumors in adolescent and young adult patients

Laura Agresta (2018)

10.1002/pbc.28636

Safety and efficacy of gamma‐secretase inhibitor nirogacestat (PF‐03084014) in desmoid tumor: Report of four pediatric/young adult cases

T. Takahashi (2020)

10.3892/ol.2020.12304

Management of aggressive fibromatosis

Zhongyuan Zhang (2021)

10.1093/jjco/hyaa125

Effectiveness of doxorubicin-based and liposomal doxorubicin chemotherapies for patients with extra-abdominal desmoid-type fibromatosis: a systematic review.

Koki Shimizu (2020)

Some data provided by SemanticScholar